Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: Results from the multicentric FACE-SZ dataset

Schizophrenia Bulletin

Volumn 42, Issue 5, 2016, Pages 1290-1302

  Bulzacka, Ewa ^a,b,c,r   Boyer, Laurent ^a,d   Schürhoff, Franck ^a,e,r   Godin, Ophélia ^a,f,g   Berna, Fabrice ^a,h   Brunel, Lore ^a,b,c,r   Andrianarisoa, Méja ^a,b,c,r   Aouizerate, Bruno ^a,i,j,s   Capdevielle, Delphine ^a,k   Chéreau Boudet, Isabelle ^a,e   Chesnoy Servanin, Gabrielle ^a,l   Danion, Jean Marie ^a,h   Dubertret, Caroline ^a,m   Dubreucq, Julien ^a,n   Faget, Catherine ^a,o   Gabayet, Franck ^a,n   Le Gloahec, Tifenn ^a,b,c,r   Llorca, Pierre Michel ^a,e   Mallet, Jasmina ^a,m,o   Misdrahi, David ^a,i,p,t   Rey, Romain ^a,l   Richieri, Raphaëlle ^a,o   Passerieux, Christine ^a,q,u   Roux, Paul ^a,q   Yazbek, Hanan ^a,k   Leboyer, Marion ^a,b,c,r   Fond, Guillaume ^a,b,c,r   Blanc, Olivier ^a,e   D'Amato, Thierry ^a,l   Arnaud, Deloge ^a,i,t   Delorme, Claire ^a,n   Denizot, Hélène ^a,e   Dorey, Jean Michel ^a,l   Fluttaz, Cécile ^a,u   Fonteneau, Sandrine ^a,u   Giraud Baro, Elisabeth ^a,n   Hardy Baylé, Marie Christine ^a,u   Lacelle, Delphine ^a,e   Lançon, Christophe ^a,o   Laouamri, Hakim ^a   Le Strat, Yann ^a,m   Metairie, Emeline ^a,o   Offerlin Meyer, Isabelle ^a,h   Peri, Pauline ^a,o   Pires, Sylvie ^a,e   Portalier, Céline ^a,m   Roman, Céline ^a,n   Sebilleau, Mathilde ^a,u   Schandrin, Aurélie ^a,k   Tessier, Arnaud ^a,i,t   Tronche, Anne Marie ^a,e   Urbach, Mathieu ^a,u   Vaillant, Florence ^a,o   Vehier, Aurélie ^a,l   Vidailhet, Pierre ^a,h   Vilà, Estelle ^a,i,t   Zinetti Bertschy, Anna ^a,h   more..

^a FONDATION FONDAMENTAL   (France)

^b INSERM U955   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j INSTITUT FRANÇOIS MAGENDIE   (France)

^k MONTPELLIER UNIVERSITY HOSPITAL   (France)

^l UNIVERSITÉ LYON 1   (France)

^m HÔPITAL LOUIS MOURIER   (France)

ⁿ Centre Referent de Rehabilitation Psychosociale   (France)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^p UMR 5287   (France)

^q LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^r ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^s CENTRE HOSPITALIER CHARLES PERRENS   (France)

^t Charles Perrens Hospital   (France)

^u CENTRE HOSPITALIER DE VERSAILLES   (France)

more..

Author keywords

C reactive protein (CRP); Cognition; Cognitive impairment; Inflammation; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT;

ABNORMAL VALUE; ABSTRACT REASONING; ADDICTION; ADULT; AGE; ARTICLE; ATTENTION TEST; CALIFORNIA VERBAL LEARNING TEST; CHRONIC INFLAMMATION; COGNITION; COGNITIVE DEFECT; COMMUNITY LIVING; COMORBIDITY; CONTINUOUS PERFORMANCE TEST IDENTICAL PAIRS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DOORS TEST; EDUCATIONAL STATUS; FEMALE; HUMAN; INTELLIGENCE; LEARNING; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL ARITHMETIC; MENTAL FUNCTION; MENTAL PATIENT; NATIONAL ADULT READING TEST; NONVERBAL MEMORY TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RECALL; RECOGNITION; SCHIZOPHRENIA; SEMANTIC MEMORY; SEX; SYMPTOMATOLOGY; TRAIL MAKING TEST; VISUAL ATTENTION; WECHSLER ADULT INTELLIGENCE SCALE; WORKING MEMORY; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; COMPLICATION; INFLAMMATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

ADULT; C-REACTIVE PROTEIN; CHRONIC DISEASE; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 85007623571     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbw029     Document Type: Article

References (92)

1. Fernandes BS, Steiner J, Bernstein H-G, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry. 2015;21:554-564. Doi:10.1038/mp.2015.87.
2. Fond G, d'Albis M-A, Jamain S, et al. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull. 2015;41:559-573.
3. Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:102-111.
4. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia. Clin Schizophr Relat Psychoses. 2014;7:223-230.
5. Dickerson F. Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia. Evid Based Ment Health. 2015;18:e2-e2.
6. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Vives AH, Cleare AJ. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 2015;25:1532-1543.
7. Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord. 2013;150:736-744.
8. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150:456-459.
9. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14:21. Doi:10.1615/CritRevNeurobiol.v14.i1.10.
10. Zipursky RB, Reilly TJ, Murray RM. The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2013;39:1363-1372.
11. Laurin D, Curb JD, Masaki KH, White LR, Launer LJ. Midlife C-reactive protein and risk of cognitive decline: a 31-year follow-up. Neurobiol Aging. 2009;30:1724-1727.
12. Mancinella A, Mancinella M, Carpinteri G, et al. Is there a relationship between high C-reactive protein (CRP) levels and dementia? Arch Gerontol Geriatr. 2009;49:185-194.
13. Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement. 2009;5:318-323.
14. Kuo H-K, Yen C-J, Chang C-H, Kuo C-K, Chen J-H, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005;4:371-380.
15. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93:261-265.
16. Joseph J, Depp C, Martin AS, et al. Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups. Schizophr Res. 2015;168:456-460.
17. Schurhoff F, Fond G, Berna F, et al. A National network of schizophrenia expert centres: an innovative tool to bridge the research-practice gap. Eur Psychiatry. 2015;30: 728-735.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
19. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res. 1992;6:201-208.
20. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
21. Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex J Devoted Study Nerv Syst Behav. 1978;14:234-244.
22. Mackinnon A, Mulligan R. [The estimation of premorbid intelligence levels in French speakers]. L'Encéphale. 2005;31:31-43.
23. Wechsler D, Coalson DL, et Raiford SE. WAIS-IV: Wechsler adult intelligence scale. San Antonio, TX: Pearson; 2008.
24. Ryan JJ, Ward LC. Validity, reliability, and standard errors of measurement for two seven-subtest short forms of the Wechsler Adult Intelligence Scale-III. Psychol Assess. 1999;11:207.
25. Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271-276.
26. Godefroy O. Fonctions executives et pathologies neurologiques et psychiatriques: evaluation en pratique clinique. Groupe de Boeck. 2008.
27. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test. San Antonio, TX: The Psychological Corporation. Harcourt Assessment Company; 2000.
28. Poitrenaud J, Deweer B, Kalafat M, Van der Linden M. Adaptation en langue francaise du California Verbal Learning Test. Paris Éditions Cent Psychol Appliquée. 2007.
29. Baddeley AD, Emslie H, Nimmo-Smith I. Doors and people: a test of visual and verbal recall and recognition. Thames Valley Test Company. 1994.
30. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213.
31. Thalheimer W, Cook S. How to calculate effect sizes from published research: a simplified methodology. Work-Learn Res. 2002;1-9.
32. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures. Pharmacoeconomics. 1999;15:141-155.
33. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care. 1989;27:S178-189.
34. Tabachnick BG, Fidell LS. Using Multivariate Statististics. Boston, MA: Allyn and Bacon Pearson Education Company; 2001.
35. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93:261-265.
36. Bender R, Lange S. Adjusting for multiple testing-when and how? J Clin Epidemiol. 2001;54:343-349.
37. Aas M, Dazzan P, Mondelli V, Melle I, Murray RM, Pariante CM. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation. Front Psychiatry. 2014;4:182.
38. Chung YS, Barch D, Strube M. A meta-analysis of mentalizing impairments in adults with schizophrenia and autism spectrum disorder. Schizophr Bull. 2014;40:602-616.
39. Fioravanti M, Bianchi V, Cinti ME. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry. 2012;12:64.
40. Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150:42-50.
41. Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res. 2015;161:102-112.
42. Wersching H, Duning T, Lohmann H, et al. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology. 2010;74:1022-1029.
43. Fraguas D, Diaz-Caneja CM, Pina-Camacho L, Janssen J, Arango C. Progressive brain changes in children and adolescents with early-onset psychosis: a meta-analysis of longitudinal MRI studies. Schizophr Res. 2014.
44. Tse MT, Piantadosi PT, Floresco SB. Prefrontal cortical gamma-aminobutyric acid transmission and cognitive function: drawing links to schizophrenia from preclinical research. Biol Psychiatry. 2015;77:929-939.
45. Zhou Y, Ma X, Wang D, et al. The selective impairment of resting-state functional connectivity of the lateral subregion of the frontal pole in schizophrenia. PloS One. 2015;10:e0119176.
46. Davis J, Moylan S, Harvey BH, Maes M, Berk M. Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust N Z J Psychiatry. 2014;48:512-529.
47. Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res. 2015;161:102-112.
48. Chang HH, Lee IH, Gean PW, et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun. 2012;26:90-95.
49. Krogh J, Benros ME, Jorgensen MB, Vesterager L, Elfving B, Nordentoft M. The association between depressive symptoms, cognitive function, and inflammation in major depression. Brain Behav Immun. 2014;35:70-76.
50. Fond G, Godin O, Brunel L, et al. Peripheral sub-inflammation is associated with antidepressant consumption in schizophrenia. Results from the multi-center FACE-SZ data set. J Affect Disord. 2016;191:209-215.
51. Amidi A, Wu LM, Agerbaek M, et al. Cognitive impairment and potential biological and psychological correlates of neuropsychological performance in recently orchiectomized testicular cancer patients. Psychooncology. 2015;24:1174-1180.
52. Mangiafico RA, Sarnataro F, Mangiafico M, Fiore CE. Impaired cognitive performance in asymptomatic peripheral arterial disease: relation to C-reactive protein and D-dimer levels. Age Ageing. 2006;35:60-65.
53. Marsland AL, Gianaros PJ, Kuan DC-H, Sheu LK, Krajina K, Manuck SB. Brain morphology links systemic inflammation to cognitive function in midlife adults. Brain Behav Immun. 2015;48:195-204.
54. Shucard JL, Gaines JJ, Ambrus J, Shucard DW. C-reactive protein and cognitive deficits in systemic lupus erythematosus. Cogn Behav Neurol Off J Soc Behav Cogn Neurol. 2007;20:31-37.
55. Baddeley A. Working memory: looking back and looking forward. Nat Rev Neurosci. 2003;4:829-839.
56. Bettcher BM, Wilheim R, Rigby T, et al. C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun. 2012;26:103-108.
57. Semmler A, Okulla T, Sastre M, Dumitrescu-Ozimek L, Heneka MT. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat. 2005;30:144-157.
58. Akrivos J, Ravona-Springer R, Schmeidler J, et al. Glycemic control, inflammation, and cognitive function in older patients with type 2 diabetes. Int J Geriatr Psychiatry. 2015;30:1093-1100.
59. Elderkin-Thompson V, Irwin MR, Hellemann G, Kumar A. Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults. Am J Geriatr Psychiatry. 2012;20:753-763.
60. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA. Association of C-reactive protein with cognitive impairment. Arch Neurol. 2010;67:87-92.
61. Teunissen CE, Van Boxtel MPJ, Bosma H, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol. 2003;134:142-150.
62. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia. Schizophr Bull. 2000;26:119-136.
63. Kessler RK, Giovannetti T, MacMullen LR. Everyday action in schizophrenia: performance patterns and underlying cognitive mechanisms. Neuropsychology. 2007;21:439.
64. Penades R, Catalan R, Puig O, et al. Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia. Psychiatry Res. 2010;177:41-45.
65. Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2012;38:304-315.
66. Gunstad J, Bausserman L, Paul RH, et al. C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J Clin Neurosci Off J Neurosurg Soc Australas. 2006;13:540-546.
67. Heringa SM, van den Berg E, Reijmer YD, et al. Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the Hoorn Study. Psychoneuroendocrinology. 2014;40:108-118.
68. Schram MT, Euser SM, de Craen AJM, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007;55:708-716.
69. Faugere M, Micoulaud-Franchi JA, Alessandrini M, et al. Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study. Sci Rep. 2015;5:10793. Doi:10.1038/srep10793.
70. Micoulaud-Franchi J-A, Faugere M, Boyer L, et al. Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. Schizophr Res. 2015;165:94-96.
71. Wu MD, Hein AM, Moravan MJ, Shaftel SS, Olschowka JA, O'Banion MK. Adult murine hippocampal neurogenesis is inhibited by sustained IL-1ß and not rescued by voluntary running. Brain Behav Immun. 2012;26:292-300.
72. Koo JW, Duman RS. IL-1ß is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci. 2008;105:751-756.
73. Goshen I, Kreisel T, Ounallah-Saad H, et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology. 2007;32:1106-1115.
74. Cacci E, Claasen J-H, Kokaia Z. Microglia-derived tumor necrosis factor-a exaggerates death of newborn hippocampal progenitor cells in vitro. J Neurosci Res. 2005;80:789-797.
75. Aravena O, Pesce B, Soto L, et al. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-?-producing NK cell and regulatory T cell subsets. Immunobiology. 2011;216:1256-1263.
76. Sommer IE, van Westrhenen R, Begemann MJH, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2013, sbt139.
77. Fond G, Hamdani N, Kapczinski F, et al. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand. 2014;129:163-179.
78. Schaub N, Reichlin T, Meune C, et al. Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction. Clin Chem. 2012;58:246-256.
79. Godin O, Leboyer M, Gaman A, et al. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: results from the FACE-SZ cohort. Schizophr Res. 2015.
80. Vincenzi B, Stock S, Borba CPC, et al. A randomized placebo- controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophr Res. 2014;159:395-403.
81. Fond G, Girerd N, Clavel F, Tamouza R, Leboyer M. Recently discovered properties of aspirin may be doubly helpful in bipolar disorders. Med Hypotheses. 2014;82:640-641.
82. Kelley BJ, McClure LA, Unverzagt FW, et al. Regular aspirin use does not reduce risk of cognitive decline. J Am Geriatr Soc. 2015;63:390-392.
83. Wichmann MA, Cruickshanks KJ, Carlsson CM, et al. NSAID use and incident cognitive impairment in a population- based cohort. Alzheimer Dis Assoc Disord. 2015.
84. Nilsson A, Tovar J, Johansson M, Radeborg K, Bjorck I. A diet based on multiple functional concepts improves cognitive performance in healthy subjects. Nutr Metab. 2013;10:49.
85. Creswell JD, Irwin MR, Burklund LJ, et al. Mindfulness-Based Stress Reduction training reduces loneliness and pro-inflammatory gene expression in older adults: a small randomized controlled trial. Brain Behav Immun. 2012;26:1095-1101.
86. Wolf SA, Melnik A, Kempermann G. Physical exercise increases adult neurogenesis and telomerase activity, and improves behavioral deficits in a mouse model of schizophrenia. Spec Issue Adapt Immun Cent Nerv Syst Funct. 2011;25:971-980.
87. Fond G, Godin O, Llorca PM, Leboyer M. Abnormal C-reactive protein (CRP) levels in schizophrenia and schizoaffective disorders. Results from the FACE-SZ dataset. Eur Psychiatry. 2015;30:S112.
88. Barzilay R, Lobel T, Krivoy A, Shlosberg D, Weizman A, Katz N. Elevated C-reactive protein levels in schizophrenia inpatients is associated with aggressive behavior. Eur Psychiatry. 2016;31:8-12.
89. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003;107:499-511.
90. Sicras-Mainar A, Rejas-Gutierrez J, Navarro-Artieda R, Blanca-Tamayo M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur Psychiatry. 2013;28:161-167.
91. Wysokinski A, Margulska A, Strzelecki D, Kloszewska I. Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry. 2015;69:346-353.
92. Boyer L, Richieri R, Dassa D, et al. Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatry Res. 2013;210:381-386.